Meta Pixel

News and Announcements

One on One Interview with Founder of ECS Capital – Charles Sidman

  • Published April 26, 2021 12:00AM UTC
  • Publisher Wholesale Investor
  • Categories Company Updates

Sidney Macdessi sits with Charles Sidman, the founder and managing partner of U.S. based Venture Capital firm ECS Capital Partners, LLC, to discuss the active investor mindset and process of due diligence.

Sidney and Charles discuss:

  • Investing in DeepTech/BioTech/MedTech
  • The Advantages of a Scientific Background When Investing
  • His 4 Stages of Due Diligence
  • The Importance of Multi-Stage Investing

Register Interest

About ECS Capital Partners

ECS Capital Partners is a venture capital firm investing globally in innovative seed and growth-stage deep-tech companies that promise high financial return and positive human, social or environmental impact (especially in health, sustainable energy and materials, food/Ag, education, communication, transportation, fintech, etc.). Due to a unique structure and operating style, ECS is itself innovative and impactful, completely investor-focused, highly networked and collaborative, globally active, evergreen, and offers individualized account management for accredited individual and institutional investors of all sizes. We are passionately committed, diligent, creative, confident yet humble.

For individuals or entities not presently participating in or obtaining adequate results from this asset class, due to constraints of experience, access, finances or time, perceptions of risk, or the systemic impediments to smaller investors’ success, ECS provides a diversified, multi-stage, professionally managed but individually shaped portfolio of high-return impact investments. Broadly based but critically selected and managed, such a portfolio approaches an “Intelligent Index Fund” for this asset class.

Register Interest

Capital Insights
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer

In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]

Capital Insights
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts

As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.

Join over 45,000+ sophisticated investors

Join Now